Program:
The difficulty of developing effective therapies for HIV
infection is compounded by the length of time required to
get answers to clinical evaluations based solely on long-
term mortality. The relatively loose correlation between
CD4 counts and outcome has made it imperative that other
surrogate markers, such as viral load, be validated. The
use of quantified gene amplification and other surrogate
markers will be of use not only in clinical drug evaluation,
but may also prove crucial for better timing and choice of
more individualized therapy.
Registration :
Cambridge Healthtech Institute
1037 Chestnut Street
Newton Upper Falls, MA 02164 USA
tel: 617-630-1300
fax: 617-630-1325
Deadline for Abstracts: 8/95
Email for Requests and Registration: chi@healthtech.com